What we have achieved
We have joined a broad network of partner organizations, the Cryptococcal Meningitis Action Group, advocating for better access to life-saving treatment combinations for people with cryptococcal meningitis. Ending cryptococcal meningitis deaths by 2030 is its overarching goal.
What we are doing for people living with cryptococcal meningitis
Our aim is to facilitate the scale-up of key medicines in selected, trailblazer African low- and middle-income countries through a comprehensive action plan. We are also working to develop a better formulation of the existing medicines.
An improved formulation of a key medicine. We are developing a formulation of an HIV-related cryptococcal meningitis medicine that can be taken orally or through a nasogastric tube. The medicine only needs to be taken twice a day rather than four times a day.
Address the supply and demand barriers limiting access to immediate-release flucytosine and liposomal amphotericin B for cryptococcal meningitis in low- and middle-income countries.
Building capacity, uniting expertise
Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.